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Introduction
Nanomedicines generally utilise 2 approaches; orally delivered solid drug nanoparticles (SDNs) or injected drug carriers[1-3]. Oral delivery remains the preferred route of administration in the
treatment of certain chronic diseases largely due to practicality. However, nanocarriers are rarely administered orally. This is in-part due to the challenges associated with the diffusion of intact
particulates from the gut and into the systemic circulation. Delivery of intact particulates is often a prerequisite for subsequent downstream targeting strategies and a greater understanding of the
mechanisms that underpin these processes are required for informed particle design[4-6]. Orally delivered nanocarriers may be worth exploring further for certain diseases, like HIV, where daily
injectables have failed to meet clinical needs. Aims: To investigate the suitability of polymeric nanoparticles with differing surface functionalities for the oral delivery of a poorly water-soluble
compound and investigate the mechanisms that underpin the translocation of nanocarriers across Caco-2 monolayers as a model for the intestinal epithelium, utlising various pharmacological
inhibitors.
Discussion
• Two distinct polymeric nanocarriers were developed with either PEG or dendron surface functionalisation and loaded with the traceable hydrophobic dye Fluoresceinamine.
• Differences in Fluoresceinamine’s ability to accumulate and transverse Caco-2 monolayers suggested distinct mechanisms of particle uptake and translocation between delivery platforms.
• Co-incubation of the nanocarriers with various clathrin- and caveolae-mediated endocytosis inhibitors suggested the PEG surface functionalised nanocarriers utilised a predominantly endocytic
process to allow Fluoresceinamine to translocate across the monolayer. However, translocation was not effected when delivered using the amine functional dendron nanocarriers suggesting an
alternative translocation route, possibly involving paracellular processes.
• These data provide in vitro support for permeation of intact nanocarriers across the intestinal epithelium via distinct mechanisms that appear to be highly dependent on surface composition.
• Tuneable oral absorption of intact nanocarriers potentially allows for drug targeting that is adaptable for specific disease requirements and therefore warrants further investigation.
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Results 
Nanoparticle characteristics
Polymeric nanocarriers were prepared using a nanoprecipitation technique and surface
functionalised with either PEG or amine functional dendron. The lipophilic dye,
Fluoresceinamine was encapsulated into the nanocarriers and used as a traceable surrogate for
insoluble drugs. The characteristics of the particles used in the study are outlined in Figure 1.
A B
Figure 1. Dynamic light scattering analysis of (A) PEG surface functionalised and (B) amine functional
dendron nanocarrier suspensions (Malvern Instruments, UK).
Cellular Accumulation The Cellular Accumulation Ratio (CAR)
of both unformulated and nanocarrier
encapsulated Fluoresceinamine was
determined in (A) Caco-2 and (B)
ATHP-1 cells. Figure 2, suggests up to
a 2- and 4.5-fold increase in the
accumulation of Fluoresceinamine in
Caco-2 and ATHP-1 cells, respectively,
when treated with the amine
functionalised dendron nanocarriers,
compared with the unformulated
preparation. The Caco-2 and ATHP-1
cells treated with PEG functionalised
nanocarriers displayed comparable or
reduced accumulation compared to
the unformulated control.
A B
Figure 2. CAR of Fluoresceinamine in (A) Caco-2 and
(B) ATHP-1 cells following 4 h incubation at 37oC 5%
CO2 with unformulated or nanocarrier encapsulated
Fluoresceinamine.
**, P<0.01; and ***, P<0.001 (ANOVA) (n=4)
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Figure 4. The Papp of Fluoresceinamine
following incubation with the inhibitors:
chlorpromazine (Chl); dansylcadaverine (Dan);
genistein (Gen) or Indomethacin (Ind) with
unformulated or nanocarrier encapsulated
equivalents. Monolayers were pre-incubated
for 30 min with the outlined inhibitors and co-
incubated for 4 h at 37oC 5% CO2.***, P <0.001
(ANOVA) (n=4).
Figure 3. The Papp ratio of unformulated and nanocarrier
encapsulated Fluoresceinamine. Monolayers were incubated
for 4 h at 37oC 5% CO2. **, P<0.01; and ***, P<0.001
(ANOVA) (n=4)
The results in Figure 3 indicate that the
PEG and amine functional dendron
nanocarriers increased the apparent oral
absorption of Fluoresceinamine over 5-
and 3-fold, respectively, compared to the
unformulated equivalent. Suggesting an
overall increase in the absorption of
Fluoresceinamine from the gut and into
the systemic circulation.
An investigation into the effects of co-incubating
Caco-2 monolayers with both clathrin- and
caveolae-mediated endocytosis inhibitors and
unformulated or nanocarrier encapsulated
Fluoresceinamine revealed significant differences
in the dyes ability to transverse the monolayer
(Figure 4):
• All the inhibitors caused a significant reduction
in Fluoresceinamine Papp when delivered via
the PEG-functionalised nanocarriers. Up to a
70% reduction in Papp was observed.
• Variable Fluoresceinamine Papp was observed
when the monolayers were incubated with the
amine functional dendron nanocarriers,
regardless of inhibitor.
• Co-incubation of the monolayers with the
unformulated preparation and endocytosis
inhibitors led to an overall increase in
Fluoresceinamine Papp.
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